These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35165917)

  • 21. Efficient adaptive designs with mid-course sample size adjustment in clinical trials.
    Bartroff J; Lai TL
    Stat Med; 2008 May; 27(10):1593-611. PubMed ID: 18275090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.
    Connor JT; Broglio KR; Durkalski V; Meurer WJ; Johnston KC
    Trials; 2015 Mar; 16():72. PubMed ID: 25885963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
    Mauer M; Collette L; Bogaerts J;
    Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive designs from a Data Safety Monitoring Board perspective: Some controversies and some case studies.
    Turnbull BW
    Clin Trials; 2017 Oct; 14(5):462-469. PubMed ID: 28178849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An objective re-evaluation of adaptive sample size re-estimation: commentary on 'Twenty-five years of confirmatory adaptive designs'.
    Mehta C; Liu L
    Stat Med; 2016 Feb; 35(3):350-8. PubMed ID: 26757953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs.
    Herrmann C; Rauch G
    Methods Inf Med; 2021 May; 60(1-02):1-8. PubMed ID: 33648007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size re-estimation in adaptive enrichment design.
    Lin R; Yang Z; Yuan Y; Yin G
    Contemp Clin Trials; 2021 Jan; 100():106216. PubMed ID: 33246098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.
    Shih WJ; Li G; Wang Y
    Contemp Clin Trials; 2016 Mar; 47():40-8. PubMed ID: 26674739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size re-estimation for pivotal clinical trials.
    Liu Y; Xu H
    Contemp Clin Trials; 2021 Mar; 102():106215. PubMed ID: 33217555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of adaptive designs with respect to a performance score.
    Herrmann C; Kieser M; Rauch G; Pilz M
    Biom J; 2022 Aug; 64(6):989-1006. PubMed ID: 35426460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A practical guide to Bayesian group sequential designs.
    Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
    Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of Bayesian interim analysis and classical interim analysis in group sequential design].
    Yuan L; Zhan Z; Tan X
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1638-42. PubMed ID: 26607091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Power Derivative Principle, and Its Application to How and When to Perform a One-Shot Unblinded Reassessment Sample Size.
    Blondiaux E; Derobert E
    Ther Innov Regul Sci; 2020 Jan; 54(1):117-127. PubMed ID: 32008247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.